0001062993-17-003141.txt : 20170707 0001062993-17-003141.hdr.sgml : 20170707 20170706195841 ACCESSION NUMBER: 0001062993-17-003141 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20170703 FILED AS OF DATE: 20170707 DATE AS OF CHANGE: 20170706 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Merus Labs International Inc. CENTRAL INDEX KEY: 0001031516 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30082 FILM NUMBER: 17953666 BUSINESS ADDRESS: STREET 1: 100 WELLINGTON ST. WEST STREET 2: SUITE 2110 P.O. BOX 151 CITY: TORONTO STATE: A6 ZIP: M5K 1H1 BUSINESS PHONE: 416 593-3701 MAIL ADDRESS: STREET 1: 100 WELLINGTON ST. WEST STREET 2: SUITE 2110 P.O. BOX 151 CITY: TORONTO STATE: A6 ZIP: M5K 1H1 FORMER COMPANY: FORMER CONFORMED NAME: ENVOY CAPITAL GROUP INC. DATE OF NAME CHANGE: 20090223 FORMER COMPANY: FORMER CONFORMED NAME: ENVOY COMMUNICATIONS GROUP INC DATE OF NAME CHANGE: 19970127 6-K 1 form6k.htm FORM 6-K Merus Labs International Inc. - Form 6-K - Filed by newsfilecorp.com

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2017

Commission File No. 00-30082

MERUS LABS INTERNATIONAL INC.
(Translation of registrant's name into English)

100 Wellington St. West, Suite 2110 P.O. Box 151
Toronto, ON M5K 1H1
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
Form 20-F [   ]      Form 40-F [X]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) [   ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7) [   ]

SUBMITTED HEREWITH


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: July 7, 2017

MERUS LABS INTERNATIONAL INC.

/s/ Dr. Michael Bumby
______________________________________
Dr. Michael Bumby
Chief Financial Officer

EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Merus Labs International Inc. - Exhibit 99.1 - Filed by newsfilecorp.com

Merus Labs International Inc. and Norgine B.V. receive Spanish anti-trust approval of proposed Arrangement

TORONTO, Ontario — July 3, 2017 — Merus Labs International Inc. (TSX: MSL, NASDAQ: MSLI) (“Merus” or the “Company”) and Norgine B.V. (“Norgine”) announced today that Norgine’s proposed acquisition of all of the issued and outstanding common shares of Merus (the “Shares”) by way of plan of arrangement (the “Arrangement”) has been approved by the Spanish anti-trust authority, the Comisión Nacional de los Mercados y la Competencia. This was the only regulatory approval required to be obtained as a condition to completion of the Arrangement.

On July 10, 2017 at 10:00 a.m., at the offices of Torys LLP, 79 Wellington St. West, 33rd Floor, TD South Tower, M5K 1N2, Toronto, Ontario, Canada, Merus will hold a special shareholder meeting (the “Meeting”) whereby shareholders will be asked to approve the Arrangement. Shareholders must vote by 10:00 a.m., Toronto time, on July 6, 2017.

Subject to approval of the Arrangement by shareholders holding at least 66⅔% of the Shares present in person or represented by proxy at the Meeting, court approval and certain other closing conditions customary for transactions of this nature, it is anticipated that the Arrangement will be completed on or about July 17, 2017.

For more information, please contact Laurel Hill Advisory Group at 1-877-452-7184 (toll-free), 416-304-0211 (collect calls outside of North America) or assistance@laurelhill.com.

About Merus

Merus is a specialty pharmaceutical company focused on acquiring and optimizing legacy and growth products. The Company leverages its expertise and scalable platform across Europe, Canada and select other markets to deliver value.

About Norgine

Norgine is a leading European specialist pharmaceutical company with a direct commercial presence in all major European markets. In 2016, Norgine’s total revenue was €368 million, including product sales, partnering milestones and other income. Norgine employs over 1,000 people across its commercial, development and manufacturing operations and manages all aspects of product development, production, marketing, sale and supply. Norgine specialises in gastroenterology, hepatology, cancer and supportive care. Norgine is headquartered in the Netherlands. Norgine owns a R&D site in Hengoed, Wales and two manufacturing sites in Hengoed, Wales and Dreux, France. For more information, please visit www.norgine.com.

In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com.

CONTACT:

For Further Information on Merus: Dr. Michael Bumby, CFO, T: +1.905.726.0995, info@meruslabs.com, www.meruslabs.com;

For Further Information on Norgine: Christopher Bath, CFO, T: +44(0)1895 453723; Media: Isabelle Jouin, T: +44 (0)1895 453643; Follow us @norgine; www.norgine.com